Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.
Market Analysis and Insights: Global Human Prothrombin Complex Market
Due to the COVID-19 pandemic, the global Human Prothrombin Complex market size is estimated to be worth US$ 1778.9 million in 2022 and is forecast to a readjusted size of US$ 3473.8 million by 2028 with a CAGR of 11.8% during the review period. Fully considering the economic change by this health crisis, 500 IU/Vial accounting for % of the Human Prothrombin Complex global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hemophilia B segment is altered to an % CAGR throughout this forecast period.
Global Human Prothrombin Complex key players include Octapharma, Shire, CSL, etc. Global top three manufacturers hold a share over 75%.
North America is the largest market, with a share about 45%, followed by Europe, and Asia-Pacific, both have a share about 45 percent.
In terms of product, 500 IU/Vial is the largest segment, with a share over 50%. And in terms of application, the largest application is Hemophilia B, followed by Vitamin K Deficiency, etc.
Global Human Prothrombin Complex Scope and Segment
Human Prothrombin Complex market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Human Prothrombin Complex market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
500 IU/Vial
600 IU/Vial
1000 IU/Vial
Others
Segment by Application
Hemophilia B
Vitamin K Deficiency
Others
By Company
Takeda
CSL
Grifols
Octapharma
Hualan Biological
Meheco Xinxing Pharma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Market Analysis and Insights: Global Human Prothrombin Complex Market
Due to the COVID-19 pandemic, the global Human Prothrombin Complex market size is estimated to be worth US$ 1778.9 million in 2022 and is forecast to a readjusted size of US$ 3473.8 million by 2028 with a CAGR of 11.8% during the review period. Fully considering the economic change by this health crisis, 500 IU/Vial accounting for % of the Human Prothrombin Complex global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hemophilia B segment is altered to an % CAGR throughout this forecast period.
Global Human Prothrombin Complex key players include Octapharma, Shire, CSL, etc. Global top three manufacturers hold a share over 75%.
North America is the largest market, with a share about 45%, followed by Europe, and Asia-Pacific, both have a share about 45 percent.
In terms of product, 500 IU/Vial is the largest segment, with a share over 50%. And in terms of application, the largest application is Hemophilia B, followed by Vitamin K Deficiency, etc.
Global Human Prothrombin Complex Scope and Segment
Human Prothrombin Complex market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Human Prothrombin Complex market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
500 IU/Vial
600 IU/Vial
1000 IU/Vial
Others
Segment by Application
Hemophilia B
Vitamin K Deficiency
Others
By Company
Takeda
CSL
Grifols
Octapharma
Hualan Biological
Meheco Xinxing Pharma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
